Diabetes and obesity
Our licensing opportunities tagged with Diabetes and obesity are shown below.
Bulk acoustic wave (BAW) sensors based on micromechanical systems (MEMS) offer significant advantages over quartz crystal microbalance (QCM); such as compact size, compatibility with electronics, lower power consumption, lower cost and higher reliability. However, their wide application to real-world detection remains limited by the temperature-dependence of their performance. Recently researchers at the University of Cambridge have developed a novel Film Bulk Acoustic Resonator (FBAR) device which has the potential to overcome this limitation by enabling the simultaneous measurement of temperature and mass loading in a single device without increasing their size or adding complexity to the electronics. Through the use of a novel multi-layer device structure and electrode materials, temperature self-referenced FBAR resonators with high operating frequencies (~1-2 GHz) and world-leading Q-factors (>1500) have been produced paving the way for real-world monitoring using FBAR sensors.
Key potential benefits:
Parallel sensing of several physical variables within the same unit sensor
Small size (around 150μm × 150μm)
Ultrahigh sensitivity ( in range of 10-14 to 10-15g)
Tuneable frequency of actuation (suitable for >1 GHz applications)
System for monitoring and controlling levels of glucose in type 1 diabetes patients using an interacting multiple model strategy.
Executable and source code to represent glucose regulation of type 1 diabetes.
Enables exploration of mechanisms involved in glucose dependent insulinotropic polypeptide secretion with the potential to identify targets in these cells that could be exploited therapeutically for treatment of obesity.
Enables exploration of mechanisms underlying GLP-1, PYY and glucagon release, with the potential to identify targets in proglucagon-expressing cells that could be exploited therapeutically for the treatment of diabetes and obesity.